Journal profile · Genetics & Heredity
Current Gene Therapy
ISSN 1566-5232 · eISSN 1875-5631 · Bentham Science Publishers B.V. · NETHERLANDS · Quarterly · Founded 2001
Current Gene Therapy: CAS Zone 4 · Medicine (2025 upgraded edition); impact factor 4; hybrid open access; median 96 days to acceptance (70 articles, last 24 months); community-reported acceptance: moderate; 72 articles in 2025; indexed in SCIE and Scopus.
Scope
Aims, scope and focus
Current Gene Therapy is published by Bentham Science Publishers B.V. and is in Zone 4 of Medicine in the CAS Journal Ranking (2025 upgraded edition). By OpenAlex counts of its recent articles, its largest topics are Virus-based gene therapy research, RNA Interference and Gene Delivery and CRISPR and Genetic Engineering, together about 51% of its articles. Its main subfields are Molecular Biology. (generated from OpenAlex topic counts and CAS ranking data)
Current Gene Therapy is a bi-monthly peer-reviewed journal aimed at academic and industrial scientists with an interest in major topics concerning basic research and clinical applications of gene and cell therapy of diseases. Cell therapy manuscripts can also include application in diseases when cells have been genetically modified. Current Gene Therapy publishes full-length/mini reviews and original research on the latest developments in gene transfer and gene expression analysis, vector development, cellular genetic engineering, animal models and human clinical applications of gene and cell therapy for the treatment of diseases. Current Gene Therapy publishes reviews and original research containing experimental data on gene and cell therapy. The journal also includes manuscripts on technological advances, ethical and regulatory considerations of gene and cell therapy. Reviews should provide the reader with a comprehensive assessment of any area of experimental biology applied to molecular medicine that is not only of significance within a particular field of gene therapy and cell therapy but also of interest to investigators in other fields. Authors are encouraged to provide their own assessment and vision for future advances. Reviews are also welcome on late breaking discoveries on which substantial literature has not yet been amassed. Such reviews provide a forum for sharply focused topics of recent experimental investigations in gene therapy primarily to make these results accessible to both clinical and basic researchers. Manuscripts containing experimental data should be original data, not previously published.
Source: LetPub
Research area (LetPub): Genetics & Heredity
Main research topics OpenAlex counts of recent articles; shares are approximate
- Virus-based gene therapy researchBiochemistry, Genetics and Molecular Biology24.5%
- RNA Interference and Gene DeliveryBiochemistry, Genetics and Molecular Biology14.2%
- CRISPR and Genetic EngineeringBiochemistry, Genetics and Molecular Biology12.3%
- Viral Infectious Diseases and Gene Expression in InsectsBiochemistry, Genetics and Molecular Biology5.4%
- Cancer Research and TreatmentsBiochemistry, Genetics and Molecular Biology4.8%
- CAR-T cell therapy researchMedicine4%
- Animal Genetics and ReproductionBiochemistry, Genetics and Molecular Biology3.4%
- Pluripotent Stem Cells ResearchBiochemistry, Genetics and Molecular Biology3.3%
Rankings & indexing
CAS ranking and database indexing
CAS Journal Ranking
CAS Journal Ranking, upgraded edition (March 2025)Medicine Zone 4
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 4 |
| Minor | Genetics & Heredity | Zone 4 |
Top journal: noReview journal: no
CAS Xinrui Journal Ranking (March 2026)Medicine Zone 3
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 3 |
| Minor | Genetics & Heredity | Zone 3 |
Top journal: noReview journal: not marked
CAS Journal Ranking, previous upgraded edition (December 2023)Medicine Zone 4
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 4 |
| Minor | Genetics & Heredity | Zone 4 |
Top journal: noReview journal: yes
Database indexing
SCIEScopusLetPub
International journal early-warning lists: not listed in any editionLetPub
Editions, and major and minor categories, are shown separately and never merged into one zone; check which edition your institution uses before you submit or report.
Metrics
Impact metrics and publication volume
Impact
- Impact factor
- 4LetPub ·
- CiteScore 2026-06
- 6.7LetPub ·
- SJR 2026-06
- 0.71LetPub ·
- SNIP 2026-06
- 0.63LetPub ·
- h-index
- 65LetPub ·
- h-index
- 90OpenAlex ·
- i10-index
- 743OpenAlex ·
- 2-year mean citedness
- 4.02OpenAlex ·
- Self-citation rate
- 2.4%LetPub ·
- Share of gold OA articles
- 6.45%LetPub ·
Volume
- Articles per year
- 64LetPub ·
Articles by year OpenAlex count · 1,263 in total · the current year is incomplete
| Year | Articles | Open access | Citations |
|---|---|---|---|
| 2026 | 61 | 0 | 18 |
| 2025 | 72 | 8 | 252 |
| 2024 | 52 | 4 | 474 |
| 2023 | 40 | 5 | 328 |
| 2022 | 37 | 3 | 318 |
| 2021 | 60 | 8 | 818 |
Sources count differently and were observed at different times, so each source's own value is kept; "publisher" marks figures from the journal's website.
Review & acceptance
Review time and acceptance
Review time from article dates manuscript dates registered with Crossref · to
96 daysMedian, submission to acceptance · P25–P75 75 days – 116 days
- Acceptance to online
- median 159 days (70 articles)
- Submission to online
- median 288 days
- Sample
- 70 articles with submission and acceptance dates (175 in the window); the latest was accepted on
Only articles that were accepted and published are counted, not the time spent on rejected manuscripts, so this usually runs longer than a publisher's "time to first decision".
Other sources
- Average acceptance (community reports)
- ModerateLetPub ·
Community reports come from authors' own submissions (confidence 0.5) and are not a promise from the journal; for publisher figures, the journal's own definitions apply.
Fees & open access
APC and open-access policy
Hybrid open accessLetPub
A subscription journal in which authors can pay to publish their article open access.
No source has fee information yet; check the journal's website.
A hybrid journal charges the APC only when the author chooses open access; publishing under the subscription model is usually free.
The journal's website is authoritative for fees; sources were observed at different times and each keeps its own value, without averaging.
Profile
Publication details and official links
- Publisher
- Bentham Science Publishers B.V.
- Country or region
- NETHERLANDS
- Language
- English
- Frequency
- Quarterly
- Founded
- 2001
- ISSN
- 1566-5232
- Electronic ISSN
- 1875-5631
- Official links
- Journal homepage ↗OpenAlex
- Submission system ↗LetPub
FAQ
Frequently asked questions about Current Gene Therapy
What CAS zone is Current Gene Therapy in?
In the 2025 upgraded edition of the CAS Journal Ranking, Current Gene Therapy is in Zone 4 of Medicine, and in Zone 4 of the minor category Genetics & Heredity. In the 2026 Xinrui edition it is in Zone 3 of Medicine. Zones from different editions, and from major and minor categories, are not interchangeable.
What is the impact factor of Current Gene Therapy?
The latest impact factor listed by LetPub is 4; CiteScore 6.7, h-index 90.
How long does peer review take at Current Gene Therapy?
Based on the dates recorded on 70 articles published between October 2024 and October 2026 (the last 24 months), the median time from submission to acceptance is 96 days (interquartile range 75–116 days); the community-reported acceptance is “Moderate”. Article statistics cover accepted papers only, publisher figures follow the journal's own definitions, and community reports come from authors' own submissions; none is a promise from the journal.
Which databases index Current Gene Therapy?
According to LetPub and DOAJ records, Current Gene Therapy is indexed in SCIE and Scopus.
Is Current Gene Therapy open access, and what is the APC?
Current Gene Therapy is a hybrid journal. Fee information is not available yet; check the journal's website.
Sources and updates
The facts on this page come from LetPub, OpenAlex; every figure is tagged with its source and the date it was observed, and conflicting values are kept per source. LetPub source page: view ↗ (archived 2026-08-24). Last updated: .